The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
|Articles|February 24, 2014
- Gastrointestinal Cancers (Issue 1)
- Volume 1
- Issue 1
The Treatment of Advanced Colorectal Cancer
Author(s)Roberto Bordonaro, MD
Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer.
Advertisement
Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer (CRC).
Read more about the treatment of CRC andthe need for fullRASmutational analyses > >
Articles in this issue
over 12 years ago
The Identification of Molecular Subtypes of Gastric Cancerover 12 years ago
Ramucirumab Combo Increases Survival in Gastric Cancerover 12 years ago
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Dataover 12 years ago
New Standard of Neoadjuvant Care for Rectal Cancer Establishedover 12 years ago
Reducing the Risk of Relapse in Patients With Pancreatic Cancerover 12 years ago
Vismodegib Demonstrates Activity in Advanced Pancreatic CancerAdvertisement
Related to this article
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer
5